TWI693071B - 硫化寡醣在製備治療手術後肝細胞癌病患之藥物的用途 - Google Patents
硫化寡醣在製備治療手術後肝細胞癌病患之藥物的用途 Download PDFInfo
- Publication number
- TWI693071B TWI693071B TW107106359A TW107106359A TWI693071B TW I693071 B TWI693071 B TW I693071B TW 107106359 A TW107106359 A TW 107106359A TW 107106359 A TW107106359 A TW 107106359A TW I693071 B TWI693071 B TW I693071B
- Authority
- TW
- Taiwan
- Prior art keywords
- hepatocellular carcinoma
- patients
- tumor
- invasion
- liver
- Prior art date
Links
- 206010073071 hepatocellular carcinoma Diseases 0.000 title claims abstract description 79
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title claims abstract description 79
- 239000003814 drug Substances 0.000 title claims abstract description 59
- 238000002271 resection Methods 0.000 title claims abstract description 28
- 229920001542 oligosaccharide Polymers 0.000 title abstract description 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 150000002482 oligosaccharides Chemical class 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 88
- 230000004083 survival effect Effects 0.000 claims abstract description 54
- 230000009545 invasion Effects 0.000 claims abstract description 52
- 201000010099 disease Diseases 0.000 claims abstract description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 42
- 210000004185 liver Anatomy 0.000 claims abstract description 31
- 230000009790 vascular invasion Effects 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims description 60
- 229940079593 drug Drugs 0.000 claims description 51
- 238000001356 surgical procedure Methods 0.000 claims description 19
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 9
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 9
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 9
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 9
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 9
- 208000014018 liver neoplasm Diseases 0.000 claims description 9
- 210000004204 blood vessel Anatomy 0.000 claims description 8
- 230000002980 postoperative effect Effects 0.000 claims description 8
- 241000700721 Hepatitis B virus Species 0.000 claims description 7
- 238000012752 Hepatectomy Methods 0.000 claims description 6
- 241000711549 Hepacivirus C Species 0.000 claims description 5
- 229940124405 anti-hepatitis b virus drug Drugs 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 238000001647 drug administration Methods 0.000 claims 1
- 239000000902 placebo Substances 0.000 description 40
- 229940068196 placebo Drugs 0.000 description 40
- 238000004458 analytical method Methods 0.000 description 32
- 230000034994 death Effects 0.000 description 23
- 231100000517 death Toxicity 0.000 description 23
- 230000000694 effects Effects 0.000 description 18
- 238000000034 method Methods 0.000 description 14
- 230000001681 protective effect Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 11
- 238000009098 adjuvant therapy Methods 0.000 description 9
- 230000001186 cumulative effect Effects 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 230000002411 adverse Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000009499 grossing Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 6
- 238000002591 computed tomography Methods 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 230000036962 time dependent Effects 0.000 description 6
- 230000002668 anti-heparin effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- -1 manganese sulfide phosphate Chemical compound 0.000 description 5
- 241000700605 Viruses Species 0.000 description 4
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 238000000491 multivariate analysis Methods 0.000 description 4
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 4
- 238000007473 univariate analysis Methods 0.000 description 4
- 108010022901 Heparin Lyase Proteins 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 230000003412 degenerative effect Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 230000007775 late Effects 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 2
- 101710144268 B- and T-lymphocyte attenuator Proteins 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 208000007660 Residual Neoplasm Diseases 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 2
- 101710090983 T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960001997 adefovir Drugs 0.000 description 2
- 229960003205 adefovir dipivoxil Drugs 0.000 description 2
- 230000003527 anti-angiogenesis Effects 0.000 description 2
- 229940124404 anti-hepatitis c virus drug Drugs 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000010102 embolization Effects 0.000 description 2
- 229960000980 entecavir Drugs 0.000 description 2
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 210000002767 hepatic artery Anatomy 0.000 description 2
- 208000010710 hepatitis C virus infection Diseases 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 229960001627 lamivudine Drugs 0.000 description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 2
- 108010025001 leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000009022 nonlinear effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229960003930 peginterferon alfa-2a Drugs 0.000 description 2
- 229960003931 peginterferon alfa-2b Drugs 0.000 description 2
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229960000329 ribavirin Drugs 0.000 description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 2
- 238000011272 standard treatment Methods 0.000 description 2
- 229960005311 telbivudine Drugs 0.000 description 2
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 description 2
- 229960004556 tenofovir Drugs 0.000 description 2
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000000058 Anaplasia Diseases 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 101710114790 Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 208000028622 Immune thrombocytopenia Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 238000012351 Integrated analysis Methods 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 102000007295 Mucin-3 Human genes 0.000 description 1
- 108010008701 Mucin-3 Proteins 0.000 description 1
- 208000013544 Platelet disease Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000010109 chemoembolization Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- FKRSSPOQAMALKA-CUPIEXAXSA-N daclatasvir Chemical group COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)=CN1 FKRSSPOQAMALKA-CUPIEXAXSA-N 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- OBMNJSNZOWALQB-NCQNOWPTSA-N grazoprevir Chemical compound O=C([C@@H]1C[C@@H]2CN1C(=O)[C@@H](NC(=O)O[C@@H]1C[C@H]1CCCCCC1=NC3=CC=C(C=C3N=C1O2)OC)C(C)(C)C)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C OBMNJSNZOWALQB-NCQNOWPTSA-N 0.000 description 1
- 229960002914 grazoprevir Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000012002 interactive response technology Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000009021 linear effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 229960000518 ombitasvir Drugs 0.000 description 1
- UAUIUKWPKRJZJV-MDJGTQRPSA-N paritaprevir Chemical compound C1=NC(C)=CN=C1C(=O)N[C@@H]1C(=O)N2C[C@H](OC=3C4=CC=CC=C4C4=CC=CC=C4N=3)C[C@H]2C(=O)N[C@]2(C(=O)NS(=O)(=O)C3CC3)C[C@@H]2\C=C/CCCCC1 UAUIUKWPKRJZJV-MDJGTQRPSA-N 0.000 description 1
- 229960002754 paritaprevir Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011470 radical surgery Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 230000034655 secondary growth Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229960002063 sofosbuvir Drugs 0.000 description 1
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762465170P | 2017-03-01 | 2017-03-01 | |
| US62/465,270 | 2017-03-01 | ||
| US201762504552P | 2017-05-11 | 2017-05-11 | |
| US62/504,552 | 2017-05-11 | ||
| US201762551770P | 2017-08-29 | 2017-08-29 | |
| US62/551,770 | 2017-08-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201840324A TW201840324A (zh) | 2018-11-16 |
| TWI693071B true TWI693071B (zh) | 2020-05-11 |
Family
ID=63357147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW107106359A TWI693071B (zh) | 2017-03-01 | 2018-02-26 | 硫化寡醣在製備治療手術後肝細胞癌病患之藥物的用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10842804B2 (https=) |
| JP (1) | JP6948080B2 (https=) |
| KR (1) | KR102265159B1 (https=) |
| CN (1) | CN110381953A (https=) |
| TW (1) | TWI693071B (https=) |
| WO (1) | WO2018157762A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113160911A (zh) * | 2021-02-26 | 2021-07-23 | 杭州臻合健康科技有限公司 | 一种用于术前肝功能耐受性分析的评估系统 |
| CN117476246B (zh) * | 2023-12-25 | 2024-04-19 | 福建大数据一级开发有限公司 | 基于多类型复发事件的患者生存分析方法、介质及装置 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103788141B (zh) * | 2004-03-04 | 2016-08-17 | 普罗吉恩制药有限公司 | 硫酸化寡聚糖衍生物 |
| KR20140050605A (ko) | 2011-06-09 | 2014-04-29 | 메디젠 바이오테크놀로지 코프 | 간암의 재발, 악화 또는 전이 억제용 의약조성물 |
-
2018
- 2018-02-08 US US15/892,343 patent/US10842804B2/en active Active
- 2018-02-24 JP JP2019547371A patent/JP6948080B2/ja active Active
- 2018-02-24 CN CN201880014397.6A patent/CN110381953A/zh active Pending
- 2018-02-24 WO PCT/CN2018/077105 patent/WO2018157762A1/en not_active Ceased
- 2018-02-24 KR KR1020197028654A patent/KR102265159B1/ko active Active
- 2018-02-26 TW TW107106359A patent/TWI693071B/zh active
Non-Patent Citations (4)
Also Published As
| Publication number | Publication date |
|---|---|
| JP6948080B2 (ja) | 2021-10-13 |
| TW201840324A (zh) | 2018-11-16 |
| WO2018157762A1 (en) | 2018-09-07 |
| KR102265159B1 (ko) | 2021-06-17 |
| KR20190120339A (ko) | 2019-10-23 |
| JP2020509035A (ja) | 2020-03-26 |
| CN110381953A (zh) | 2019-10-25 |
| US10842804B2 (en) | 2020-11-24 |
| US20180250317A1 (en) | 2018-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Willemze et al. | Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | |
| US20240360235A1 (en) | Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment | |
| US7976842B2 (en) | Treatment of metastatic breast cancer | |
| Melisi et al. | Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial | |
| IL270888B2 (en) | Systems and methods for identifying cancer treatments from normalized Biosman scores | |
| JP2020514311A (ja) | がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ | |
| CN107750165A (zh) | 借助塞里班土单抗的组合治疗 | |
| TWI693071B (zh) | 硫化寡醣在製備治療手術後肝細胞癌病患之藥物的用途 | |
| Zhang et al. | A phase II randomized trial of individualized neoantigen peptide vaccine combined with unusual radiotherapy (iNATURE) in advanced solid tumors-GCOG0028 | |
| JP2026053570A (ja) | Ｋｒａｓ ｇ１２ｃ変異を含む癌を治療するためのソトラシブ及びｅｇｆｒ抗体 | |
| TW202043273A (zh) | 用於晚期實性瘤癌症之治療性ｒｎａ | |
| Qiu et al. | The debatable role of immune checkpoint blockade therapy in lung adenocarcinoma-oriented liver metastatic malignant lesions | |
| US20250186584A1 (en) | Methods of treating biliary tract cancer using anti-pd-l1 antibody in combination with chemotherapy | |
| TW202529802A (zh) | 胃癌和／或胃食管結合部癌的治療 | |
| Achaiber sing et al. | P07. 19. AA COMPREHENSIVE DRUG-DISCOVERY AND CLINICAL TRIAL PLATFORM FOR GLIOBLASTOMA PATIENTS. REDIRECCT: REPURPOSING DRUGS IN RESEARCH AND CANCER CLINICAL TRIALS. | |
| Subudhi | A pilot trial to explore the link between immunological changes, efficacy, safety and tolerability of durvalumab (MEDI4736) plus tremelimumab in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (CRPC) | |
| CONFIDENTIAL et al. | A Phase 1b Study to Evaluate safety and clinical activity of Pembrolizumab (MK-3475) in combination with Chemotherapy as Neoadjuvant Treatment for Triple Negative Breast Cancer (TNBC)-(KEYNOTE 173) | |
| Schmid et al. | Pembrolizumab Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Triple-Negative Breast Cancer: Results from the Phase 1b Open-Label, Multicohort KEYNOTE-173 Study | |
| EA051386B1 (ru) | Соторасиб и антитело к egfr для лечения рака, предусматривающего мутацию kras g12c | |
| EP4698674A1 (en) | Methods to treat glioma in subjects with defined tumour microenvironment | |
| Sundahl et al. | Randomized Phase 1 Trial of Pembrolizumab with Neo-Adjuvant Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma | |
| Coffey et al. | Management of early breast cancer in women over 90: A 10 year experience | |
| Vavolizza | MEL 64 | |
| YEAR | ANNUAL RESEARCH PROGRESS REPORT | |
| code VHIO19001 | Phase II Study of Avelumab plus chemotherapy in the peri-operative treatment for patients with resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC) |